Dr. Deborah Fuller is a Professor in the Department of Microbiology at the University of Washington School of Medicine and Chief of the Infectious Diseases and Translational Medicine Division at the Washington National Primate Research Center. Prior to her academic career, Dr. Fuller worked in biotechnology developing novel vaccines against HIV and emerging infectious diseases. In 2004, she transitioned to academia where she continued her research developing novel nucleic acid vaccine platform technologies for the prevention and immunotherapy of infectious diseases and recently, developed a vaccine for COVID-19 that is scheduled to enter human clinical trials in Fall 2020. Dr. Fuller is a co-founder of a biotechnology company, Orlance, Inc (www.orlance.com) that aims to advance the most promising nucleic acid vaccines developed in her lab to clinical testing. She is a member of the National Institute of Allergy and Infectious Diseases (NIAID) Vaccines for Microbial Diseases (VMD) study section and is currently serving on the National Primate Research Centers Operations Leadership Group to accelerate preclinical evaluation of promising COVID-19 vaccines and antivirals nationwide. She has led the translation of two vaccines from bench to human clinical trials, authored over 80 manuscripts and is a co-inventor on over a dozen patents for vaccines and antivirals against infectious diseases.